学術情報 -AJRCCM(ブルージャーナル)-

本誌は、American Thoracic Society(米国胸部学会)の発行するAmerican Journal of Respiratory and Critical Care Medicineをもとに、シュプリンガー・ジャパン株式会社が公正中立の立場で論文選択、翻訳等を含む作業全般を担っている医療関係者向けの資材です。

弊社は、医療関係者に有益な情報を提供することを通じて医療に貢献することを目的に本資材の提供を行っており、本資材作成にかかる費用を負担しています。

本資材には本邦における未承認の医薬品、効能・効果及び用法・用量等の情報が含まれる場合がありますが、これを推奨するものではありません。

本資材を受領される際には、以下の内容をご確認いただきたく存じます。

  • 本資材に記載された薬剤の使用にあたっては、最新の添付文書をご参照ください。
  • 本資材は医療関係者からの求めに応じて提供するものであり、企業が積極的に提供するものではありません。

2020年01月 -PART 02-

アスベスト曝露患者における胸膜プラークと肺癌リスク

Pleural Plaques and the Risk of Lung Cancer in Asbestos-exposed Subjects
Am J Respir Crit Care Med 2020; 201(1): 57‒62

原発性移植片機能不全では肺の自然リンパ球の組成が変化する

Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction
Am J Respir Crit Care Med 2020; 201(1): 63‒72

呼吸器ウイルス感染時のIFN-β応答のダイナミクス
-治療戦略に関する洞察-

Dynamics of IFN-β Responses during Respiratory Viral Infection
Insights for Therapeutic Strategies
Am J Respir Crit Care Med 2020; 201(1): 83‒94

2020年01月 -PART 01-

中等症から重症の症状を伴う慢性閉塞性肺疾患(COPD)に対するTargeted Lung Denervation後の安全性及び有害事象の評価(AIRFLOW)
-多施設共同無作為化比較臨床試験-

Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW)
A Multicenter Randomized Controlled Clinical Trial
Am J Respir Crit Care Med 2019; 200(12): 1477‒1486

右心不全を伴う特発性肺線維症患者におけるニンテダニブとシルデナフィルの併用効果
-二重盲検無作為化臨床試験(INSTAGE試験)の事前計画に基づくサブグループ解析-

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction
A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)
Am J Respir Crit Care Med 2019; 200(12): 1505‒1512

異なる呼吸器検体によるXpert Ultraを用いた小児結核の診断

Tuberculosis Diagnosis in Children Using Xpert Ultra on Different Respiratory Specimens
Am J Respir Crit Care Med 2019; 200(12): 1531‒1538

Selected articles from AJRCCM. Copyright 2018 by the American Thoracic Society. All rights reserved. The ideas and opinions expressed in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) or other associated publications do not necessarily reflect those of the American Thoracic Society (ATS). The authors, editors or ATS are not responsible for errors or omissions of articles published in print or online from AJRCCM or other associated ATS publications. Although great care has been taken in compiling the content of this publication, neither ATS or their servants are responsible or liable in any way for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising there from. Approved product information should be reviewed before prescribing. The mention of any product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ATS assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. 

The translation is © 2018 American Thoracic Society. American Thoracic Society or Springer Healthcare takes no responsibility for the accuracy of the translation from the published English original and are not liable for any errors that may occur.